Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 37
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Cancer Diagn Progn ; 4(1): 57-65, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38173669

RESUMO

Background/Aim: Patients diagnosed with cancer are expected to choose one or more treatment modalities after receiving corresponding explanations of the options. When making these choices, patients consider the effects of treatment and aspects related to their quality of life. These concerns can cause confusion and conflict owing to the complicated information provided by medical caregivers. The objective of the study was to identify perceptions of cancer treatment in patients with cancer and the decision-making factors affecting their treatment choices. Patients and Methods: In this observational (cross-sectional) study, an online questionnaire survey was administered to 194 Japanese cancer patients with treatment experience. Patient information, perceptions of explanations provided by healthcare professionals, treatment views, and reasons for treatment decisions were subjected to a simple tabulation. Content and factor analysis was conducted to determine important treatment selection elements. Results: Regarding treatment perception, 60.3% of respondents (n=117) considered treatment a financial and family burden, 47.4% (n=92) had concerns about physical pain, and 40.2% (n=78) were worried about increased stress. Regarding decision-making quality, 95.9% determined their preferred treatment within one week, 49.0% reported difficulties in making their decisions, and 83.0% chose their treatment themselves. Major decisive factors were prolonging life, opinions of medical staff, and accepting treatment risks (68.0%, 68.6%, and 60.3% of patients, respectively). The main attitudes toward treatment were anxiety, expectations of benefit, and expectations of support and care. Conclusion: SDM should enable patients to visualize the changes that their bodies will experience and include discussions on prognosis. Psychological care should be prioritized to alleviate anxiety and improve readiness for decision-making; attention should be paid to the extent and timing of information provision.

2.
Future Oncol ; 19(33): 2263-2272, 2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-37905530

RESUMO

Background: We investigated factors involved in decision-making support provided by physicians, nurses, pharmacists and medical and psychiatric social workers involved in cancer care. Materials & methods: A questionnaire survey on decision-making support was conducted. The level of clinician support was classified as 'supporting patients' 'decision-making process regarding cancer treatment', 'no support for patients' 'decision-making process regarding cancer treatment' or 'team-based support for patients' 'decision-making process regarding cancer treatment'. Results: Physicians estimated that 83.7% of patients made a cancer treatment decision within 1 week, but 45.4% of patients had difficulty making a decision. Conclusion: Medical personnel should support patients who have difficulty making decisions, establish a screening method to identify those needing support and develop a system providing decision-making support through interprofessional work.


We conducted a survey to investigate issues related to the level of decision-making support provided by physicians, nurses, pharmacists medical social workers and psychiatric social workers involved in cancer care. The physicians reported that 83.7% of patients with cancer chose a treatment plan within 1 week, although 45.4% of patients had difficulty making a decision. These decision-making difficulties arose at the time of diagnosis, when having difficulty controlling adverse events and when cancer metastasis or recurrence occurred. Some medical providers supported patients who had particular difficulty in choosing their cancer treatment, others provided no support, while a third group orchestrated a team to support them in their decision-making. To improve the quality of decision-making support, interprofessional work should be promoted and screening tools to identify those who need support should be established.


Assuntos
Neoplasias , Médicos , Humanos , Pessoal de Saúde , Neoplasias/terapia , Atitude do Pessoal de Saúde , Corpo Clínico , Tomada de Decisões
3.
Digestion ; 104(5): 335-347, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37054692

RESUMO

BACKGROUND: Peutz-Jeghers syndrome (PJS) is a rare disease characterized by the presence of hamartomatous polyposis throughout the gastrointestinal tract, except for the esophagus, along with characteristic mucocutaneous pigmentation. It is caused by germline pathogenic variants of the STK11 gene, which exhibit an autosomal dominant mode of inheritance. Some patients with PJS develop gastrointestinal lesions in childhood and require continuous medical care until adulthood and sometimes have serious complications that significantly reduce their quality of life. Hamartomatous polyps in the small bowel may cause bleeding, intestinal obstruction, and intussusception. Novel diagnostic and therapeutic endoscopic procedures such as small-bowel capsule endoscopy and balloon-assisted enteroscopy have been developed in recent years. SUMMARY: Under these circumstances, there is growing concern about the management of PJS in Japan, and there are no practice guidelines available. To address this situation, the guideline committee was organized by the Research Group on Rare and Intractable Diseases granted by the Ministry of Health, Labour and Welfare with specialists from multiple academic societies. The present clinical guidelines explain the principles in the diagnosis and management of PJS together with four clinical questions and corresponding recommendations based on a careful review of the evidence and involved incorporating the concept of the Grading of Recommendations Assessment, Development and Evaluation system. KEY MESSAGES: Herein, we present the English version of the clinical practice guidelines of PJS to promote seamless implementation of accurate diagnosis and appropriate management of pediatric, adolescent, and adult patients with PJS.


Assuntos
Endoscopia por Cápsula , Síndrome de Peutz-Jeghers , Adolescente , Humanos , Adulto , Criança , Síndrome de Peutz-Jeghers/diagnóstico , Síndrome de Peutz-Jeghers/genética , Síndrome de Peutz-Jeghers/terapia , Qualidade de Vida , Pólipos Intestinais/patologia , Intestino Delgado/patologia
4.
Int J Clin Oncol ; 26(8): 1353-1419, 2021 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-34185173

RESUMO

Hereditary colorectal cancer (HCRC) accounts for < 5% of all colorectal cancer cases. Some of the unique characteristics commonly encountered in HCRC cases include early age of onset, synchronous/metachronous cancer occurrence, and multiple cancers in other organs. These characteristics necessitate different management approaches, including diagnosis, treatment or surveillance, from sporadic colorectal cancer management. There are two representative HCRC, named familial adenomatous polyposis and Lynch syndrome. Other than these two HCRC syndromes, related disorders have also been reported. Several guidelines for hereditary disorders have already been published worldwide. In Japan, the first guideline for HCRC was prepared by the Japanese Society for Cancer of the Colon and Rectum (JSCCR), published in 2012 and revised in 2016. This revised version of the guideline was immediately translated into English and published in 2017. Since then, several new findings and novel disease concepts related to HCRC have been discovered. The currently diagnosed HCRC rate in daily clinical practice is relatively low; however, this is predicted to increase in the era of cancer genomic medicine, with the advancement of cancer multi-gene panel testing or whole genome testing, among others. Under these circumstances, the JSCCR guidelines 2020 for HCRC were prepared by consensus among members of the JSCCR HCRC Guideline Committee, based on a careful review of the evidence retrieved from literature searches, and considering the medical health insurance system and actual clinical practice settings in Japan. Herein, we present the English version of the JSCCR guidelines 2020 for HCRC.

5.
J Biosci Bioeng ; 128(1): 28-32, 2019 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-30679111

RESUMO

Since cold atmospheric pressure plasma (CAP) has not only bactericidal activity but also fungicidal activity without toxic residues and thermal damage, it is considered as an alternative method for sterilization of fungi on the surfaces of perishable foodstuffs and human bodies. Aureobasidium pullulans is a ubiquitous yeast-like fungus and called black yeast because it produces melanin, a dark biological pigment. It is well known that various melanized fungi show hyper-resistance to extreme stress conditions including high levels of radioactivity. Curiously, however, there is very little information about the fungicidal effects of CAP on melanized fungi. Therefore, we herein investigated the effects of CAP on A. pullulans, using cold atmospheric argon plasma (Ar plasma). We found that ammonium sulfate repressed the synthesis of melanin in A. pullulans as well as Aureobasidium melanogenum. Although the non-melanized A. pullulans cells were efficiently killed by the exposure of Ar plasma, the melanized cells showed the significant resistance to Ar plasma as well as to hydrogen peroxide and thermal stress. In order to improve the fungicidal efficacy of Ar plasma, we examined the combination of Ar plasma and Fenton reaction. We realized that FeCl2 and FeSO4 significantly improved the sterilization efficacy of Ar plasma on the melanized A. pullulans.


Assuntos
Argônio/farmacologia , Ascomicetos , Compostos Ferrosos/farmacologia , Melaninas/metabolismo , Gases em Plasma/farmacologia , Argônio/química , Ascomicetos/efeitos dos fármacos , Ascomicetos/metabolismo , Pressão Atmosférica , Sinergismo Farmacológico , Fungicidas Industriais/farmacologia , Humanos , Engenharia Metabólica/métodos , Testes de Sensibilidade Microbiana , Saccharomyces cerevisiae/efeitos dos fármacos
6.
Ann Surg Oncol ; 22(11): 3565-73, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25707496

RESUMO

BACKGROUND: The estimation of recurrence risk remains a critical issue in relation to gastrointestinal stromal tumors (GISTs) treated with adjuvant therapy. The accuracy of the commonly used risk stratifications is not always adequate. METHODS: For this study, data were prospectively collected from 68 patients with GISTs who underwent R0 surgery between 2004 and 2009. The results from this analysis cohort were evaluated using the data obtained from an additional 40 patients in the validation cohort. Cyclin-dependent kinase 1 (CDK1)- and CDK2-specific activities were measured using a non-RI kinase assay system. RESULTS: The specific activities of CDK1 and CDK2, but not their expression, significantly correlated with recurrence. The specific activities of both CDK1 and CDK2 were independently correlated with mitosis and significantly correlated with recurrence-free survival (RFS). In the multivariate analysis, CDK2-specific activity (P = 0.0006), tumor size (P = 0.0347), and KIT deletion mutations (P = 0.0006) were significantly correlated with RFS in the analysis cohort. In the validation cohort, CDK2-specific activity (P = 0.0368) was identified as an independent prognostic factor for tumor recurrences with tumor location (P = 0.0442). CONCLUSION: The results suggest that the specific activities of CDK1 and CDK2 may reflect the proliferative activity of GISTs and that CDK2-specific activity is a good prognostic factor predicting recurrence after macroscopic complete resection of GISTs.


Assuntos
Proteína Quinase CDC2/metabolismo , Quinase 2 Dependente de Ciclina/metabolismo , Tumores do Estroma Gastrointestinal/enzimologia , Neoplasias Intestinais/enzimologia , Neoplasias Hepáticas/enzimologia , Neoplasias Peritoneais/enzimologia , Neoplasias Gástricas/enzimologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Intervalo Livre de Doença , Feminino , Tumores do Estroma Gastrointestinal/secundário , Tumores do Estroma Gastrointestinal/cirurgia , Genótipo , Humanos , Neoplasias Intestinais/patologia , Neoplasias Intestinais/cirurgia , Intestino Delgado , Neoplasias Hepáticas/secundário , Masculino , Pessoa de Meia-Idade , Mitose , Neoplasias Peritoneais/secundário , Proteínas Proto-Oncogênicas c-kit/genética , Curva ROC , Receptor alfa de Fator de Crescimento Derivado de Plaquetas/genética , Estudos Retrospectivos , Medição de Risco , Deleção de Sequência , Neoplasias Gástricas/patologia , Neoplasias Gástricas/cirurgia , Carga Tumoral , Adulto Jovem
7.
Clin J Oncol Nurs ; 18(6): 701-6, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-25427705

RESUMO

This article elucidates the nursing consultation techniques in shared decision making (SDM) for patients with cancer and their family members. Descriptive data (207 records) from the nurse-led SDM consultation facility and content analysis were used to extract the nursing consultation techniques. In addition, the order in which these techniques were used to structure the SDM process for patients with cancer was identified. The author extracted eight categories pertaining to nurse consultation techniques for the SDM process: sharing feelings, helping to identify the focus of the consultations, helping to devise a personalized recovery plan, providing information in accordance with the patient's responses, supporting the patient to understand the information provided, ensuring continued treatment and care, strengthening the patient support system, and exploring possibilities on the basis of patient needs. The identified logical order in which these techniques were applied may be useful as a guide to systematic decision-making support.


Assuntos
Comportamento Cooperativo , Tomada de Decisões , Neoplasias/terapia , Participação do Paciente , Encaminhamento e Consulta , Idoso , Humanos , Pessoa de Meia-Idade
8.
Rinsho Shinkeigaku ; 54(4): 330-3, 2014.
Artigo em Japonês | MEDLINE | ID: mdl-24807278

RESUMO

The patient is a 66-year-old man with hereditary telangiectasia. He was diagnosed with pulmonary arteriovenous malformation (PAVM), which was revealed by contrast-enhanced chest computed tomography at the age of 65. He developed headache, right homonymous hemianopsia, and right hemiparesis and was admitted to our hospital. Contrast-enhanced magnetic resonance imaging revealed multiple lesions in the left hemisphere, which indicates brain abscesses. Thus, the diagnosis of brain abscess mediated through PAVM was established. Following management with drainage and coil embolization, all neurological symptoms resolved. Therefore, coil embolization should be considered for PAVM at an early stage to prevent brain abscess, even if it is asymptomatic.


Assuntos
Malformações Arteriovenosas/complicações , Malformações Arteriovenosas/terapia , Abscesso Encefálico/etiologia , Infecções por Fusobacterium/etiologia , Artéria Pulmonar/anormalidades , Veias Pulmonares/anormalidades , Telangiectasia Hemorrágica Hereditária/complicações , Idoso , Antibacterianos/administração & dosagem , Fístula Arteriovenosa , Malformações Arteriovenosas/diagnóstico , Abscesso Encefálico/diagnóstico , Abscesso Encefálico/microbiologia , Abscesso Encefálico/terapia , Drenagem/métodos , Quimioterapia Combinada , Embolização Terapêutica/métodos , Infecções por Fusobacterium/diagnóstico , Infecções por Fusobacterium/microbiologia , Infecções por Fusobacterium/terapia , Fusobacterium nucleatum/isolamento & purificação , Humanos , Imageamento por Ressonância Magnética , Masculino , Resultado do Tratamento
9.
Bioorg Med Chem Lett ; 24(7): 1698-701, 2014 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-24631188

RESUMO

The plasmepsins are specific aspartic proteases of the malaria parasite and a potential target for developing new antimalarial agents. Our previously reported peptidomimetic plasmepsin inhibitor with modified 2-aminoethylamino substituent, KNI-10740, was tested against chloroquine sensitive Plasmodium falciparum, D6, to be highly potent, however, the inhibitor exhibited about 5 times less activity against multi-drug resistant parasite (TM91C235). We hypothesized the potency reduction resulted from structural similarity between 2-aminoethylamino substituent of KNI-10740 and chloroquine. Then, we modified the moiety and finally identified compound 15d (KNI-10823), that could avoid drug-resistant mechanism of TM91C235 strain.


Assuntos
Antimaláricos/farmacologia , Ácido Aspártico Endopeptidases/antagonistas & inibidores , Cloroquina/farmacologia , Resistência a Múltiplos Medicamentos/efeitos dos fármacos , Plasmodium falciparum/efeitos dos fármacos , Inibidores de Proteases/farmacologia , Antimaláricos/síntese química , Antimaláricos/química , Ácido Aspártico Endopeptidases/metabolismo , Cloroquina/química , Relação Dose-Resposta a Droga , Estrutura Molecular , Testes de Sensibilidade Parasitária , Inibidores de Proteases/síntese química , Inibidores de Proteases/química , Relação Estrutura-Atividade
10.
Rinsho Shinkeigaku ; 54(2): 130-4, 2014.
Artigo em Japonês | MEDLINE | ID: mdl-24583587

RESUMO

The patient was a 58-year-old man with 1-year history of cognitive decline, which was diagnosed as Alzheimer's disease in another hospital. He was admitted to our hospital for extreme fatigue, weight loss, and dysphagia, subsequent to the left peripheral facial paresis. Brain magnetic resonance (MR) imaging showed bilateral diffuse white matter lesions and hippocampal atrophy. After admission, he presented with sudden high fever, recurrent exacerbations of consciousness, and increased C-reactive protein level with marked neutrophilia, with the result that he underwent mechanical ventilation. Routine cerebrospinal fluid findings at the exacerbation were normal i.e. 4.7 cells/mm(3), 40 mg/dl of protein, but IL-6 concentration was mildly elevated to 22.2 pg/ml. After confirming the positivity of HLA (human leukocyte antigen) B54 and Cw1, we administered steroid to him and his physical activity and state of consciousness significantly improved. During the course of treatment, dermal lesion characterisitic of Sweet disease was absent. We diagnosed this case was possible neuroSweet disease proposed by Hisanaga in 2005.


Assuntos
Doenças do Sistema Nervoso Central/diagnóstico , Transtornos da Consciência/complicações , Síndrome de Sweet/diagnóstico , Antígenos HLA/análise , Humanos , Interleucina-6/líquido cefalorraquidiano , Masculino , Pessoa de Meia-Idade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA